BIOMAT Database Logo BIOMAT Database Logo

[In vitro and in vivo effects of recombinant human interleukin-3 on hematopoietic progenitor cells]. 1990

G Seipelt, and O G Ottmann, and A Ganser, and M Eder, and A Lindemann, and S Falk, and H J Stutte, and K Hübner, and R Mertelsmann, and D Hoelzer
Abteilung für Hämatologie, J. W. v. Goethe-Universität, Frankfurt.

As part of a phase I/II clinical trial with recombinant human Interleukin-3 (rhIL-3), bone marrow and peripheral blood cells from patients treated with rhIL-3 were assessed in vitro for effects on the cycling status and frequencies of erythroid, myelomonocytic and multilineage progenitor cells. Treatment with rhIL-3 induced a pronounced increase in S-phase rate of BFU-E, CFU-GEMM and day 14 CFU-GM. Circulating CFU-GEMM and day 14 CFU-GM were increased on day 7 of therapy whereas circulating BFU-E were reduced in the majority of patients. After i.v. bolus injection of IL-3 an acute effect on the peripheral blood count with neutrophilia and, after an initial nadir, monocytosis was observed. IL-6 serum-levels increased in 5 out of 14 patients after IL-3 administration with concomitant side effects in 2 patients in whom IL-6 levels increased above 75 pg/ml. In the majority of the patients a stimulation of peripheral leukocytes and platelets was observed during the 15 day treatment course. In conclusion rhIL-3 induces a multilineage response in vivo by stimulating proliferation of hemopoietic progenitor cells with a resulting elevation in peripheral blood counts.

UI MeSH Term Description Entries
D007377 Interleukin-3 A multilineage cell growth factor secreted by LYMPHOCYTES; EPITHELIAL CELLS; and ASTROCYTES which stimulates clonal proliferation and differentiation of various types of blood and tissue cells. Burst-Promoting Factor, Erythrocyte,Colony-Stimulating Factor 2 Alpha,Colony-Stimulating Factor, Mast-Cell,Colony-Stimulating Factor, Multipotential,Erythrocyte Burst-Promoting Factor,IL-3,Mast-Cell Colony-Stimulating Factor,Multipotential Colony-Stimulating Factor,P-Cell Stimulating Factor,Eosinophil-Mast Cell Growth-Factor,Hematopoietin-2,Burst Promoting Factor, Erythrocyte,Colony Stimulating Factor, Mast Cell,Colony Stimulating Factor, Multipotential,Eosinophil Mast Cell Growth Factor,Erythrocyte Burst Promoting Factor,Hematopoietin 2,Interleukin 3,Multipotential Colony Stimulating Factor,P Cell Stimulating Factor
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006412 Hematopoietic Stem Cells Progenitor cells from which all blood cells derived. They are found primarily in the bone marrow and also in small numbers in the peripheral blood. Colony-Forming Units, Hematopoietic,Progenitor Cells, Hematopoietic,Stem Cells, Hematopoietic,Hematopoietic Progenitor Cells,Cell, Hematopoietic Progenitor,Cell, Hematopoietic Stem,Cells, Hematopoietic Progenitor,Cells, Hematopoietic Stem,Colony Forming Units, Hematopoietic,Colony-Forming Unit, Hematopoietic,Hematopoietic Colony-Forming Unit,Hematopoietic Colony-Forming Units,Hematopoietic Progenitor Cell,Hematopoietic Stem Cell,Progenitor Cell, Hematopoietic,Stem Cell, Hematopoietic,Unit, Hematopoietic Colony-Forming,Units, Hematopoietic Colony-Forming
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G Seipelt, and O G Ottmann, and A Ganser, and M Eder, and A Lindemann, and S Falk, and H J Stutte, and K Hübner, and R Mertelsmann, and D Hoelzer
Recombinant human erythropoietin and hematopoietic progenitor cells in vivo.
June 1989, Blood,
G Seipelt, and O G Ottmann, and A Ganser, and M Eder, and A Lindemann, and S Falk, and H J Stutte, and K Hübner, and R Mertelsmann, and D Hoelzer
In vitro and in vivo effects of recombinant human erythropoietin on human hemopoietic progenitor cells.
January 1988, Contributions to nephrology,
G Seipelt, and O G Ottmann, and A Ganser, and M Eder, and A Lindemann, and S Falk, and H J Stutte, and K Hübner, and R Mertelsmann, and D Hoelzer
Effects of purified recombinant human interleukin-3 on the growth of human hematopoietic progenitor cells in "long-term" bone marrow culture.
January 1989, Biotechnology therapeutics,
G Seipelt, and O G Ottmann, and A Ganser, and M Eder, and A Lindemann, and S Falk, and H J Stutte, and K Hübner, and R Mertelsmann, and D Hoelzer
Effects of recombinant interleukin 11 on human megakaryocyte progenitor cells.
June 1991, Experimental hematology,
G Seipelt, and O G Ottmann, and A Ganser, and M Eder, and A Lindemann, and S Falk, and H J Stutte, and K Hübner, and R Mertelsmann, and D Hoelzer
In vitro and in vivo effects of recombinant human erythropoietin plus recombinant human G-CSF on human haemopoietic progenitor cells.
July 1994, Bone marrow transplantation,
G Seipelt, and O G Ottmann, and A Ganser, and M Eder, and A Lindemann, and S Falk, and H J Stutte, and K Hübner, and R Mertelsmann, and D Hoelzer
Synergism of interleukin 12, interleukin 3 and serum factor on primitive human hematopoietic progenitor cells.
January 1995, Stem cells (Dayton, Ohio),
G Seipelt, and O G Ottmann, and A Ganser, and M Eder, and A Lindemann, and S Falk, and H J Stutte, and K Hübner, and R Mertelsmann, and D Hoelzer
Differential effects of recombinant human interleukin-13 on the in vitro growth of human haemopoietic progenitor cells.
August 1995, British journal of haematology,
G Seipelt, and O G Ottmann, and A Ganser, and M Eder, and A Lindemann, and S Falk, and H J Stutte, and K Hübner, and R Mertelsmann, and D Hoelzer
Synergistic effects of interleukin-1 beta and interleukin-3 on the expansion of human hematopoietic progenitor cells in liquid cultures.
October 1991, Blood,
G Seipelt, and O G Ottmann, and A Ganser, and M Eder, and A Lindemann, and S Falk, and H J Stutte, and K Hübner, and R Mertelsmann, and D Hoelzer
Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo.
December 1988, Blood,
G Seipelt, and O G Ottmann, and A Ganser, and M Eder, and A Lindemann, and S Falk, and H J Stutte, and K Hübner, and R Mertelsmann, and D Hoelzer
Biologic effects of recombinant human interleukin-3 in vivo.
December 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!